Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase (PARP) Inhibitors

Therapeutic drugs that block DNA repair, including poly(ADP-ribose) polymerase (PARP) inhibitors, fail due to lack of tumor-selectivity. When PARP inhibitors and β-lapachone are combined, synergistic antitumor activity results from sustained NAD(P)H levels that refuel NQO1-dependent futile redox dru...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Cell
Main Authors: Huang, Xiumei, Motea, Edward A., Moore, Zachary R., Yao, Jun, Dong, Ying, Chakrabarti, Gaurab, Kilgore, Jessica A., Silvers, Molly A., Patidar, Praveen L., Cholka, Agnieszka, Fattah, Farjana, Cha, Yoonjeong, Anderson, Glenda G., Kusko, Rebecca, Peyton, Michael, Yan, Jingsheng, Xie, Xian-Jin, Sarode, Venetia, Williams, Noelle S., Minna, John D., Beg, Muhammad, Gerber, David E., Bey, Erik A., Boothman, David A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5161231/
https://ncbi.nlm.nih.gov/pubmed/27960087
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2016.11.006
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados